- Home
- PRME vs IMAB Comparison
PRME vs IMAB Comparison
Compare PRME & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- IMAB
- Stock Information
- Founded
- PRME 2019
- IMAB 2014
- Country
- PRME United States
- IMAB United States
- Employees
- PRME N/A
- IMAB N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- IMAB Health Care
- Exchange
- PRME Nasdaq
- IMAB Nasdaq
- Market Cap
- PRME 191.7M
- IMAB 200.9M
- IPO Year
- PRME 2022
- IMAB 2020
- Fundamental
- Price
- PRME $4.21
- IMAB $2.11
- Analyst Decision
- PRME Buy
- IMAB Strong Buy
- Analyst Count
- PRME 6
- IMAB 3
- Target Price
- PRME $9.38
- IMAB $6.33
- AVG Volume (30 Days)
- PRME 5.8M
- IMAB 392.1K
- Earning Date
- PRME 08-08-2025
- IMAB 05-15-2025
- Dividend Yield
- PRME N/A
- IMAB N/A
- EPS Growth
- PRME N/A
- IMAB N/A
- EPS
- PRME N/A
- IMAB N/A
- Revenue
- PRME $3,846,000.00
- IMAB N/A
- Revenue This Year
- PRME $104.12
- IMAB N/A
- Revenue Next Year
- PRME $108.24
- IMAB N/A
- P/E Ratio
- PRME N/A
- IMAB N/A
- Revenue Growth
- PRME 550.76
- IMAB N/A
- 52 Week Low
- PRME $1.11
- IMAB $0.60
- 52 Week High
- PRME $5.95
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- PRME 60.42
- IMAB 49.47
- Support Level
- PRME $3.71
- IMAB $2.01
- Resistance Level
- PRME $5.15
- IMAB $2.25
- Average True Range (ATR)
- PRME 0.53
- IMAB 0.13
- MACD
- PRME -0.06
- IMAB -0.03
- Stochastic Oscillator
- PRME 34.25
- IMAB 25.00
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).